Dermorphin
ResearchOpioid heptapeptide
Dermorphin is a naturally occurring heptapeptide originally isolated from amphibian skin. It has been studied in pharmacology research for its high affinity and selectivity for mu-opioid receptors. Published research has investigated its receptor binding properties and its structure-activity relationships. RaysunPeptide supplies Dermorphin for qualified research and laboratory applications.
Mechanism of Action
Acts primarily as a potent mu-opioid receptor agonist, activating opioid receptor signaling and producing analgesic and opioid-like pharmacological effects.
Key Benefits
Molecular Data
Research Indications
Pain Research
Studied as a potent mu-opioid receptor agonist with pronounced analgesic activity in experimental models.
Neuroscience
Used as a research tool for investigating opioid receptor activation and downstream signaling.
Peptide Research
Its short sequence and D-alanine substitution make it useful for studying peptide-receptor interactions.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Opioid-like pharmacological effects
- •Sedation
- •Respiratory depression risk
- •Altered gastrointestinal activity
Stop Signs (Seek Medical Attention)
- ⚠Respiratory depression
- ⚠Severe sedation
- ⚠Loss of consciousness
- ⚠Signs of opioid toxicity
Contraindications
- ✕No approved general human therapeutic indication
- ✕Research use should follow institutional safety requirements
FAQs
What is the sequence of dermorphin?
Dermorphin is a heptapeptide with the sequence Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, commonly represented as YAFGYPS with D-Ala and C-terminal amidation.
Is dermorphin FDA approved?
No. Dermorphin is primarily a research peptide and is not an FDA-approved therapeutic.
